Treatment and vaccines for severe acute respiratory syndrome
Identifieur interne : 004D32 ( Main/Exploration ); précédent : 004D31; suivant : 004D33Treatment and vaccines for severe acute respiratory syndrome
Auteurs : David A. Groneberg [Allemagne] ; Susan M. Poutanen [Canada] ; Donald E. Low [Canada] ; Hartmut Lode [Allemagne] ; Tobias Welte [Allemagne] ; Peter Zabel [Allemagne]Source :
- Lancet. Infectious diseases : (print) [ 1473-3099 ] ; 2005.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (usage thérapeutique), Flambées de maladies (), Humains, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (traitement médicamenteux), Vaccins antiviraux, Virus du SRAS (), Virus du SRAS (immunologie), Virus du SRAS (pathogénicité).
- MESH :
- immunologie : Syndrome respiratoire aigu sévère, Virus du SRAS.
- pathogénicité : Virus du SRAS.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux.
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
- Animal model, Animals, Antiviral Agents (therapeutic use), Clinical trial, Coronavirus, Disease Outbreaks (prevention & control), Epidemic, Human, Humans, Immunoprophylaxis, In vitro, Method, Mortality, Prevention, Prognosis, SARS Virus (drug effects), SARS Virus (immunology), SARS Virus (pathogenicity), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe acute respiratory syndrome, Treatment, Vaccine, Viral Vaccines.
- MESH :
- chemical , therapeutic use : Antiviral Agents.
- drug effects : SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- pathogenicity : SARS Virus.
- prevention & control : Disease Outbreaks, Severe Acute Respiratory Syndrome.
- Animals, Humans, Viral Vaccines.
Abstract
The causative agent of severe acute respiratory syndrome (SARS), which affected over 8000 individuals worldwide and was responsible for over 700 deaths in the 2002-2003 outbreak, is a coronavirus that was unknown before the outbreak. Although many different treatments were used during the outbreak, none were implemented in a controlled fashion. Thus, the optimal treatment for SARS is unknown. Since the outbreak, much work has been done testing new agents against SARS using in-vitro methods and animal models. In addition, global research efforts have focused on the development of vaccines against SARS. Efforts should be made to evaluate the most promising treatments and vaccines in controlled clinical trials, should another SARS outbreak occur.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000675
- to stream PascalFrancis, to step Curation: 000315
- to stream PascalFrancis, to step Checkpoint: 000540
- to stream Main, to step Merge: 005060
- to stream Pmc, to step Corpus: 001856
- to stream Pmc, to step Curation: 001856
- to stream Pmc, to step Checkpoint: 001198
- to stream PubMed, to step Corpus: 002843
- to stream PubMed, to step Curation: 002843
- to stream PubMed, to step Checkpoint: 002409
- to stream Ncbi, to step Merge: 000E37
- to stream Ncbi, to step Curation: 000E37
- to stream Ncbi, to step Checkpoint: 000E37
- to stream Main, to step Merge: 004812
- to stream Main, to step Curation: 004D32
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Treatment and vaccines for severe acute respiratory syndrome</title><author><name sortKey="Groneberg, David A" sort="Groneberg, David A" uniqKey="Groneberg D" first="David A." last="Groneberg">David A. Groneberg</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Pneumology, Hannover Medical School</s1><s2>Hannover</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Otto-Heubner-Centre, Pneumology and Immunology, Charité School of Medicine, Free University and Humboldt-University</s1><s2>Berlin</s2><s3>DEU</s3><sZ>1 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Poutanen, Susan M" sort="Poutanen, Susan M" uniqKey="Poutanen S" first="Susan M." last="Poutanen">Susan M. Poutanen</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology</wicri:noRegion></affiliation><affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Department of Laboratory Medicine and Pathobiology, University of Toronto</s1><s2>Toronto</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Low, Donald E" sort="Low, Donald E" uniqKey="Low D" first="Donald E." last="Low">Donald E. Low</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology</wicri:noRegion></affiliation><affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Department of Laboratory Medicine and Pathobiology, University of Toronto</s1><s2>Toronto</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Department of Medicine, University of Toronto</s1><s2>Toronto</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Lode, Hartmut" sort="Lode, Hartmut" uniqKey="Lode H" first="Hartmut" last="Lode">Hartmut Lode</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Chest and Infectious Diseases, Hospital Heckeshorn, Free University Berlin</s1><s2>Berlin</s2><s3>DEU</s3><sZ>4 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Welte, Tobias" sort="Welte, Tobias" uniqKey="Welte T" first="Tobias" last="Welte">Tobias Welte</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Pneumology, Hannover Medical School</s1><s2>Hannover</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Zabel, Peter" sort="Zabel, Peter" uniqKey="Zabel P" first="Peter" last="Zabel">Peter Zabel</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Clinical Infectiology and Immunology, Department of Medicine, Research Center Borstel</s1><s2>Borstel</s2><s3>DEU</s3><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Borstel</wicri:noRegion><wicri:noRegion>Research Center Borstel</wicri:noRegion><wicri:noRegion>Borstel</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0248001</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 05-0248001 INIST</idno><idno type="RBID">Pascal:05-0248001</idno><idno type="wicri:Area/PascalFrancis/Corpus">000675</idno><idno type="wicri:Area/PascalFrancis/Curation">000315</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000540</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000540</idno><idno type="wicri:doubleKey">1473-3099:2005:Groneberg D:treatment:and:vaccines</idno><idno type="wicri:Area/Main/Merge">005060</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106466</idno><idno type="RBID">PMC:7106466</idno><idno type="wicri:Area/Pmc/Corpus">001856</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001856</idno><idno type="wicri:Area/Pmc/Curation">001856</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001856</idno><idno type="wicri:Area/Pmc/Checkpoint">001198</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001198</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15766649</idno><idno type="wicri:Area/PubMed/Corpus">002843</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002843</idno><idno type="wicri:Area/PubMed/Curation">002843</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002843</idno><idno type="wicri:Area/PubMed/Checkpoint">002409</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002409</idno><idno type="wicri:Area/Ncbi/Merge">000E37</idno><idno type="wicri:Area/Ncbi/Curation">000E37</idno><idno type="wicri:Area/Ncbi/Checkpoint">000E37</idno><idno type="wicri:doubleKey">1473-3099:2005:Groneberg D:treatment:and:vaccines</idno><idno type="wicri:Area/Main/Merge">004812</idno><idno type="wicri:Area/Main/Curation">004D32</idno><idno type="wicri:Area/Main/Exploration">004D32</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Treatment and vaccines for severe acute respiratory syndrome</title><author><name sortKey="Groneberg, David A" sort="Groneberg, David A" uniqKey="Groneberg D" first="David A." last="Groneberg">David A. Groneberg</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Pneumology, Hannover Medical School</s1><s2>Hannover</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Otto-Heubner-Centre, Pneumology and Immunology, Charité School of Medicine, Free University and Humboldt-University</s1><s2>Berlin</s2><s3>DEU</s3><sZ>1 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Poutanen, Susan M" sort="Poutanen, Susan M" uniqKey="Poutanen S" first="Susan M." last="Poutanen">Susan M. Poutanen</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology</wicri:noRegion></affiliation><affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Department of Laboratory Medicine and Pathobiology, University of Toronto</s1><s2>Toronto</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Low, Donald E" sort="Low, Donald E" uniqKey="Low D" first="Donald E." last="Low">Donald E. Low</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology</wicri:noRegion></affiliation><affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Department of Laboratory Medicine and Pathobiology, University of Toronto</s1><s2>Toronto</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Department of Medicine, University of Toronto</s1><s2>Toronto</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Lode, Hartmut" sort="Lode, Hartmut" uniqKey="Lode H" first="Hartmut" last="Lode">Hartmut Lode</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Chest and Infectious Diseases, Hospital Heckeshorn, Free University Berlin</s1><s2>Berlin</s2><s3>DEU</s3><sZ>4 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Welte, Tobias" sort="Welte, Tobias" uniqKey="Welte T" first="Tobias" last="Welte">Tobias Welte</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Pneumology, Hannover Medical School</s1><s2>Hannover</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Zabel, Peter" sort="Zabel, Peter" uniqKey="Zabel P" first="Peter" last="Zabel">Peter Zabel</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Clinical Infectiology and Immunology, Department of Medicine, Research Center Borstel</s1><s2>Borstel</s2><s3>DEU</s3><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Borstel</wicri:noRegion><wicri:noRegion>Research Center Borstel</wicri:noRegion><wicri:noRegion>Borstel</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Lancet. Infectious diseases : (print)</title><title level="j" type="abbreviated">Lancet. Infect. dis. : (print)</title><idno type="ISSN">1473-3099</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Lancet. Infectious diseases : (print)</title><title level="j" type="abbreviated">Lancet. Infect. dis. : (print)</title><idno type="ISSN">1473-3099</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal model</term><term>Animals</term><term>Antiviral Agents (therapeutic use)</term><term>Clinical trial</term><term>Coronavirus</term><term>Disease Outbreaks (prevention & control)</term><term>Epidemic</term><term>Human</term><term>Humans</term><term>Immunoprophylaxis</term><term>In vitro</term><term>Method</term><term>Mortality</term><term>Prevention</term><term>Prognosis</term><term>SARS Virus (drug effects)</term><term>SARS Virus (immunology)</term><term>SARS Virus (pathogenicity)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe acute respiratory syndrome</term><term>Treatment</term><term>Vaccine</term><term>Viral Vaccines</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (usage thérapeutique)</term><term>Flambées de maladies ()</term><term>Humains</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Vaccins antiviraux</term><term>Virus du SRAS ()</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (pathogénicité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Viral Vaccines</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term><term>Flambées de maladies</term><term>Humains</term><term>Syndrome respiratoire aigu sévère</term><term>Immunoprophylaxie</term><term>Traitement</term><term>Prévention</term><term>Vaccin</term><term>Homme</term><term>Coronavirus</term><term>Mortalité</term><term>Epidémie</term><term>In vitro</term><term>Méthode</term><term>Modèle animal</term><term>Essai clinique</term><term>Pronostic</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term><term>Homme</term><term>Mortalité</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The causative agent of severe acute respiratory syndrome (SARS), which affected over 8000 individuals worldwide and was responsible for over 700 deaths in the 2002-2003 outbreak, is a coronavirus that was unknown before the outbreak. Although many different treatments were used during the outbreak, none were implemented in a controlled fashion. Thus, the optimal treatment for SARS is unknown. Since the outbreak, much work has been done testing new agents against SARS using in-vitro methods and animal models. In addition, global research efforts have focused on the development of vaccines against SARS. Efforts should be made to evaluate the most promising treatments and vaccines in controlled clinical trials, should another SARS outbreak occur.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Canada</li></country><region><li>Basse-Saxe</li><li>Berlin</li><li>Ontario</li></region><settlement><li>Berlin</li><li>Hanovre</li><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Allemagne"><region name="Basse-Saxe"><name sortKey="Groneberg, David A" sort="Groneberg, David A" uniqKey="Groneberg D" first="David A." last="Groneberg">David A. Groneberg</name></region><name sortKey="Groneberg, David A" sort="Groneberg, David A" uniqKey="Groneberg D" first="David A." last="Groneberg">David A. Groneberg</name><name sortKey="Lode, Hartmut" sort="Lode, Hartmut" uniqKey="Lode H" first="Hartmut" last="Lode">Hartmut Lode</name><name sortKey="Welte, Tobias" sort="Welte, Tobias" uniqKey="Welte T" first="Tobias" last="Welte">Tobias Welte</name><name sortKey="Zabel, Peter" sort="Zabel, Peter" uniqKey="Zabel P" first="Peter" last="Zabel">Peter Zabel</name></country><country name="Canada"><noRegion><name sortKey="Poutanen, Susan M" sort="Poutanen, Susan M" uniqKey="Poutanen S" first="Susan M." last="Poutanen">Susan M. Poutanen</name></noRegion><name sortKey="Low, Donald E" sort="Low, Donald E" uniqKey="Low D" first="Donald E." last="Low">Donald E. Low</name><name sortKey="Low, Donald E" sort="Low, Donald E" uniqKey="Low D" first="Donald E." last="Low">Donald E. Low</name><name sortKey="Low, Donald E" sort="Low, Donald E" uniqKey="Low D" first="Donald E." last="Low">Donald E. Low</name><name sortKey="Poutanen, Susan M" sort="Poutanen, Susan M" uniqKey="Poutanen S" first="Susan M." last="Poutanen">Susan M. Poutanen</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D32 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004D32 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:05-0248001
|texte= Treatment and vaccines for severe acute respiratory syndrome
}}
| This area was generated with Dilib version V0.6.33. |  |